Table 2.
Potential anti-pyroptotic targets in liver disease.
| Therapeutic targets | Molecules | Diseases | Subjects | References |
|---|---|---|---|---|
| NLPR3 | Glyburide | Acute liver injury (CLP model) |
male C57BL/6 mice | [26] |
| MCC950 (NLRP3 inhibitor) |
ALF (D-Gal challenge) |
male C57BL/6 mice | [129] | |
| EPO | Sepsis related liver injury (LPS challenge) |
mice | [155] | |
| TUDCA | NASH | obese mice | [77] | |
| Taurine | NAFLD NASH |
Male C57BL/6 mice | [156] | |
| Silybin | NAFLD | Male C57BL/6 mice | [153] | |
| Dihydroquercetin | ALD | Male C57BL/6 mice | [146] | |
| Chlorogenic acid | Acute liver injury (CCl4-induced) |
male Sprague-Dawley rats | [154] | |
| Scutellarin | Sepsis related liver injury (intraperitoneally injection of Escherichia coli) |
Female C57BL/6 mice | [144] | |
| Caspases | AC-YVAD-CMK (caspase-1 inhibitor) |
Acute liver injury (MSN administration) |
male C57BL/6 mice | [61] |
| IDN 6556 (pan-caspase inhibitor) |
NASH | mice | [157] | |
| IDN 6556 (pan-caspase inhibitor) |
HCV | HCV patients | [158] | |
| PF-03491390 (pan-caspase inhibitor) |
HCV | HCV patients | [159] | |
| Cathepsin B inhibitor | SIRS /sepsis (LPS challenge) |
Human KCs | [68] | |
| IL-1 | Anakinra (IL-1 inhibitor) |
ALF (D-GalN/LPS administration) |
mice | [131] |
NLPR3: NOD-like Receptor Protein 3; CLP: Cecal Ligation and Puncture; ALF: Acute Liver Failure; D-GalN: D-galactosamine; EPO: erythropoietin; LPS: lipopolysaccharide; TUDCA: Tauroursodeoxycholic acid; NASH: non-alcoholic steatohepatitis; CTSB: cathepsin B; NAFLD: Nonalcoholic fatty liver disease; ALD: Alcoholic liver disease; CCl4: carbon tetrachloride; MSN: mesoporous silica nanoparticles ;HCV: Hepatitis C virus; SIRS: systemic inflammatory response syndrome; IL-1: Interleukin-1